An editorial in the journal Lancet debates the problems of drug development for Alzheimer's disease. The feature questions why so many trials are failing at the phase 3 clinical trial stage and asks whether the animal models used prior to this are the most effective way to test the drugs. It also suggests treatments should perhaps start to focus more on the changes in the brain that happen before symptoms like memory loss start to appear. However, it notes that these are difficult to replicate in animal models...
More...
More...